299 related articles for article (PubMed ID: 34879971)
1. Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management.
West JB; Poarch K; Lumry WR
Clin Ther; 2021 Dec; 43(12):2154-2166.e1. PubMed ID: 34879971
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema.
Levy D; Caballero T; Hussain I; Reshef A; Anderson J; Baker J; Schwartz LB; Cicardi M; Prusty S; Feuersenger H; Pragst I; Manning ME
Pediatr Allergy Immunol Pulmonol; 2020 Sep; 33(3):136-141. PubMed ID: 32953229
[No Abstract] [Full Text] [Related]
3. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
[TBL] [Abstract][Full Text] [Related]
4. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema.
Craig T; Feuersenger H; Pragst I; Dang J
Allergy Asthma Proc; 2022 May; 43(3):202-208. PubMed ID: 35524357
[No Abstract] [Full Text] [Related]
6. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.
Craig T; Zuraw B; Longhurst H; Cicardi M; Bork K; Grattan C; Katelaris C; Sussman G; Keith PK; Yang W; Hébert J; Hanzlikova J; Staubach-Renz P; Martinez-Saguer I; Magerl M; Aygören-Pürsün E; Farkas H; Reshef A; Kivity S; Neri S; Crisan I; Caballero T; Baeza ML; Hernandez MD; Li H; Lumry W; Bernstein JA; Hussain I; Anderson J; Schwartz LB; Jacobs J; Manning M; Levy D; Riedl M; Christiansen S; Feuersenger H; Pragst I; Mycroft S; Pawaskar D; Jacobs I;
J Allergy Clin Immunol Pract; 2019; 7(6):1793-1802.e2. PubMed ID: 30772477
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial.
Li HH; Mycroft S; Christiansen S; Wood DN; Feuersenger H; Pawaskar D; Jacobs I
Allergy Asthma Proc; 2018 Sep; 39(5):365-370. PubMed ID: 30107868
[TBL] [Abstract][Full Text] [Related]
8. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate.
Zuraw BL; Cicardi M; Longhurst HJ; Bernstein JA; Li HH; Magerl M; Martinez-Saguer I; Rehman SM; Staubach P; Feuersenger H; Parasrampuria R; Sidhu J; Edelman J; Craig T
Allergy; 2015 Oct; 70(10):1319-28. PubMed ID: 26016741
[TBL] [Abstract][Full Text] [Related]
9. Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema.
Anderson J; Maina N
Clin Transl Allergy; 2022 Jan; 12(1):e12092. PubMed ID: 35079346
[TBL] [Abstract][Full Text] [Related]
10. Interventions for the long-term prevention of hereditary angioedema attacks.
Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
[TBL] [Abstract][Full Text] [Related]
11. Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy.
Lumry W; Templeton T; Omert L; Levy D
J Infus Nurs; 2020; 43(3):134-145. PubMed ID: 32287168
[TBL] [Abstract][Full Text] [Related]
12. [Administration of conestat alfa, human C1 esterase inhibitor and icatibant in the treatment of acute angioedema attacks in adults with hereditary angioedema due to C1 esterase inhibitor deficiency. Treatment comparison based on systematic review results].
Kawalec P; Holko P; Paszulewicz A; Obtułowicz K
Pneumonol Alergol Pol; 2013; 81(2):95-104. PubMed ID: 23420425
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial.
Levy DS; Farkas H; Riedl MA; Hsu FI; Brooks JP; Cicardi M; Feuersenger H; Pragst I; Reshef A
Allergy Asthma Clin Immunol; 2020; 16():8. PubMed ID: 32042283
[TBL] [Abstract][Full Text] [Related]
14. Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy.
Anderson J; Levy DS; Lumry W; Koochaki P; Lanar S; Henry Li H
Allergy Asthma Clin Immunol; 2021 Jun; 17(1):60. PubMed ID: 34176500
[TBL] [Abstract][Full Text] [Related]
15. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study.
Li HH; Zuraw B; Longhurst HJ; Cicardi M; Bork K; Baker J; Lumry W; Bernstein J; Manning M; Levy D; Riedl MA; Feuersenger H; Prusty S; Pragst I; Machnig T; Craig T;
Allergy Asthma Clin Immunol; 2019; 15():49. PubMed ID: 31485239
[TBL] [Abstract][Full Text] [Related]
17. Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema.
Zhang Y; Tortorici MA; Pawaskar D; Pragst I; Machnig T; Hutmacher M; Zuraw B; Cicardi M; Craig T; Longhurst H; Sidhu J
CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):158-165. PubMed ID: 29316335
[TBL] [Abstract][Full Text] [Related]
18. Hereditary Angioedema With Normal C1 Inhibitor: US Survey of Prevalence and Provider Practice Patterns.
Riedl MA; Danese M; Danese S; Ulloa J; Maetzel A; Audhya PK
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2450-2456.e6. PubMed ID: 36720386
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
Fukuda T; Yamagami K; Kawahata K; Suzuki Y; Sasaki Y; Miyagi T; Jacobs I; Lawo JP; Glassman F; Akama H; Hide M; Ohsawa I
Allergol Int; 2023 Jul; 72(3):451-457. PubMed ID: 36858856
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.
Riedl M
Clin Drug Investig; 2015 Jul; 35(7):407-17. PubMed ID: 26091744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
